{"id":474445,"date":"2020-03-17T12:38:01","date_gmt":"2020-03-17T12:38:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=474445"},"modified":"2020-03-17T12:38:01","modified_gmt":"2020-03-17T12:38:01","slug":"acromegaly-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/acromegaly-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight_474445.html","title":{"rendered":"Acromegaly Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis By DelveInsight"},"content":{"rendered":"
\"Acromegaly<\/a><\/div>\n

DelveInsight has launched a new report on Acromegaly Market Insights, Epidemiology and Market Forecast-2030<\/strong><\/p>\n

DelveInsight’s “Acromegaly <\/strong>Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Acromegaly, historical and forecasted epidemiology as well as the Acromegaly market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/em><\/p>\n

Acromegaly is a hormonal disorder that results from the availability of excessive growth hormone (GH) in the body, which is produced by the pituitary gland (a small gland in the brain). In acromegaly, the pituitary produces an immoderate amount of GH, which is resulted from benign or noncancerous tumors on the pituitary. These benign tumors are called Adenomas. Acromegaly, sometimes shows malignancy, expands beyond the areas of the pituitary gland and affects other areas of the body, such as lungs, pancreas, and adrenal glands. The symptoms in acromegaly vary from patient to patient. It can lead to unusual physical features, such as swollen hands and feet, deformities, and complications, with an impact also on muscle strength and bone health.<\/p>\n

 <\/p>\n

\"\"<\/p>\n

 <\/p>\n

Request for :- <\/strong>Acromegaly free sample page<\/a><\/p>\n

 <\/p>\n

Acromegaly Epidemiology<\/strong><\/p>\n

Acromegaly epidemiology division provide insights about historical and current Cold Agglutinin Disease (CAD) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken<\/p>\n

 <\/p>\n

Report Key facts:- <\/strong><\/p>\n

1.  <\/strong>As per the DelveInsight’s estimate, the total number of prevalent cases of acromegaly in 2017 were found to be 61,022 in the 7MM.<\/p>\n

2<\/strong>. In the US, 24,179 acromegaly cases was originated from pituitary adenomas and 1,273 from benign tumors at other sites in<\/p>\n

2017.<\/p>\n

3<\/strong>. In Japan, 10,755 prevalent cases of acromegaly was reported in 2017.<\/p>\n

 <\/p>\n

Report Key Benefits:- <\/strong><\/p>\n

1. Acromegaly<\/strong> market report covers a descriptive overview and comprehensive insight of the Acromegaly<\/strong> epidemiology Acromegaly<\/strong> market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/p>\n

2. Acromegaly<\/strong> market report provides insights on the current and emerging therapies. <\/p>\n

3. Acromegaly<\/strong> market report offers a global historical and forecasted market covering drug outreach in 7 MM.<\/p>\n

4. Acromegaly<\/strong><\/strong> market report provides an edge that will help in developing business strategies by understanding trends shaping and driving the Acromegaly<\/strong> market<\/p>\n

 <\/p>\n

“According to DelveInsight’s analysis, majority of the cases of Acromegaly is originated with adenomas at Pituitary gland and rest are because of benign tumor at other sites”<\/strong><\/p>\n

 <\/p>\n

Few key companies working on Acromegaly Disease :-<\/strong><\/p>\n

1. Ipsen Biopharmaceutical Co. <\/p>\n

2. <\/strong>Pharmacia and Upjohn<\/p>\n

3. Novartis Pharma Co. <\/p>\n

 <\/p>\n

Drugs Covered are given below:- <\/strong><\/p>\n

1. <\/strong>Somatuline Depot (lanreotide acetate)<\/p>\n

2<\/strong>. Somavert (pegvisomant)<\/p>\n

3. Sandostatin LAR Depot<\/p>\n

 <\/p>\n

Table of Contents<\/a><\/p>\n

1. Key Insights<\/span><\/p>\n

2. Executive Summary of Acromegaly<\/span><\/p>\n

3. Competitive Intelligence Analysis for Acromegaly<\/span><\/p>\n

4. Acromegaly: Market Overview at a Glance<\/span><\/p>\n

5. Acromegaly: Disease Background and Overview<\/p>\n

6. Patient Journey<\/p>\n

7. Acromegaly Epidemiology and Patient Population<\/span><\/p>\n

8. Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n

9. Unmet Needs<\/p>\n

10. Key Endpoints of Acromegaly Treatment<\/span><\/p>\n

11. Marketed Products<\/span><\/p>\n

12. Emerging Therapies<\/p>\n

13. Acromegaly: Seven Major Market Analysis<\/p>\n

14. Attribute analysis<\/p>\n

15. 7MM: Market Outlook<\/span><\/p>\n

16. Access and Reimbursement Overview of Acromegaly<\/p>\n

17. KOL Views<\/span><\/p>\n

18. Market Drivers<\/span><\/p>\n

19. Market Barriers<\/span><\/p>\n

20. Appendix<\/span><\/p>\n

20.1. Bibliography<\/span><\/p>\n

20.2. Report Methodology<\/span><\/p>\n

21. DelveInsight Capabilities<\/span><\/p>\n

22. Disclaimer<\/span><\/p>\n

23. About <\/strong>DelveInsight<\/a><\/p>\n

Why should you buy this Acromegaly market report? <\/strong><\/p>\n